Search

Displaying results 2001 - 2010 of 10000 in total
  1. Drug

    Aluminum sulfate

    go.drugbank.com/drugs/DB11239
    Approved

    Al is found in materials used in the pharmaceutical industry, and in manufactured foodstuffs, cosmetics, and tap water. … Aluminum (Al) is ubiquitous and represents the third most common element in the Earth’s crust. It most commonly exists in a combined state with various other elements.

    Products: Trim Men Styptic Pencil
  2. Drug

    Gimeracil

    go.drugbank.com/drugs/DB09257
    ApprovedInvestigational

    The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … Approved by the European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with [DB03209] and [DB09256] within the commercially available product "Teysuno".

    Synonyms: Ts-1 (TN)
  3. Drug

    Human Rho(D) immune globulin

    go.drugbank.com/drugs/DB11597
    Approved

    It was approved by FDA as treatment for suppression of rhesus (Rh) isoimmunization or chronic immune thrombocytopenic purpura (ITP) in adults.

    Products: rhophylac 300 microgram/2ml,solution for injection in pre-filled syringe
  4. Drug

    Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

    go.drugbank.com/drugs/DB10061
    ApprovedInvestigational

    four drug substances contained in each dose of vaccine. … [A253277] Several serogroups of _N. meningitidis_ - A, B, C, Y, and W-135 - known to cause meningococcal infections have been identified.

  5. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno".

  6. Drug

    Gilteritinib

    go.drugbank.com/drugs/DB12141
    ApprovedInvestigational

    [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. … This drug was approved after being designed as an orphan drug with a fast track and priority review status.[L4830]

  7. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. … Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received

  8. Drug

    Tolazamide

    go.drugbank.com/drugs/DB00839
    Approved

    A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

    Synonyms: N-(p-Toluenesulfonyl)-N'-hexamethyleniminoureaCategories: Drugs Used in Diabetes
  9. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment … The novelty of the medication lies in the fact that it is the first and only use of synthetic human angiotensin II to help maintain body blood pressure.

  10. Drug

    Nipocalimab

    go.drugbank.com/drugs/DB16257
    ApprovedInvestigational

    [L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis. … [L64042] This reduction in autoantibodies underlies its therapeutic effect across autoantibody-driven conditions.[L64042] It is administered by intravenous infusion.